PD-1 Blockers
Copyright policy )PD-1 Blockers
Nivolumab and pembrolizumab are monoclonal antibodies that block the programmed death-1 receptor (PD-1, CD279), resulting in dis-inhibition of tumor-specific immune responses. Both are recently approved for use in the treatment of metastatic melanoma, and nivolumab as well for non-small cell lung cancer.
- Memorial Sloan Kettering Cancer Center United States
Clinical Trials as Topic, Lung Neoplasms, Skin Neoplasms, Biochemistry, Genetics and Molecular Biology(all), Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, Nivolumab, Carcinoma, Non-Small-Cell Lung, Humans, Melanoma
Clinical Trials as Topic, Lung Neoplasms, Skin Neoplasms, Biochemistry, Genetics and Molecular Biology(all), Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, Nivolumab, Carcinoma, Non-Small-Cell Lung, Humans, Melanoma
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).131 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 1% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1%
Citations provided by BIP!Popularity provided by BIP!